Al-Dawaa Medical Services (4163) Fundamentals 2026 — P/E 14.4x, Revenue Analysis | SniperIQ
Al-Dawaa Medical Services (4163) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 3.4B, trading at SAR 40.48 on the SAU. This SniperIQ fundamentals page covers Al-Dawaa Medical Services's valuation (P/E 14.4x, P/B 2.4x), profitability (net margin 3.6%), revenue (SAR 6.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Al-Dawaa Medical Services's market cap?
Al-Dawaa Medical Services (4163) has a market capitalization of approximately SAR 3.4B, trading at SAR 40.48 on the SAU. Market cap moves with the live share price.
What is Al-Dawaa Medical Services's P/E ratio?
Al-Dawaa Medical Services's trailing twelve-month P/E ratio is 14.4x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Al-Dawaa Medical Services?
Al-Dawaa Medical Services runs a net profit margin of 3.6%, a gross margin of 33.4%, and an operating margin of 5.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Al-Dawaa Medical Services generate?
Al-Dawaa Medical Services reported revenue of SAR 6.7B for fiscal year 2025, with net income of SAR 322M and earnings per share (EPS) of 3.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Al-Dawaa Medical Services pay a dividend?
Al-Dawaa Medical Services offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Al-Dawaa Medical Services financially healthy?
Al-Dawaa Medical Services carries a debt-to-equity ratio of 1.55x and a current ratio of 1.18x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Al-Dawaa Medical Services a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Al-Dawaa Medical Services (4163) the key facts are: market cap SAR 3.4B, P/E 14.4x, revenue SAR 6.7B, 52-week range 40.28-76.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Al-Dawaa Medical Services's full fundamentals live
Get Al-Dawaa Medical Services's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.